Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

335.26 +2.81 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,360,579
Open 335.84
Bid (Size) 334.00 (1)
Ask (Size) 337.21 (1)
Prev. Close 332.45
Today's Range 332.92 - 337.56
52wk Range 249.70 - 346.85
Shares Outstanding N/A
Dividend Yield 2.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Bull Market Strengthened, Let The Naysayers Say Nay...
Being able to recite the potential problems in the world does not make you a good investor. 
Via Talk Markets
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs

Performance

YTD
+12.73%
+12.73%
1 Month
+2.22%
+2.22%
3 Month
+10.54%
+10.54%
6 Month
+23.76%
+23.76%
1 Year
+27.40%
+27.40%

More News

Read More
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500
Via The Motley Fool
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Via The Motley Fool
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Amgen Unusual Options Activity For August 29
Via Benzinga
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival
Via Investor's Business Daily
Growth At Any Price (GAAP) Is A Bad Strategy. Valuation Matters.
Via Talk Markets
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Smart Money Is Betting Big In AMGN Options
Via Benzinga
Patchy But Still Bullish
Via Talk Markets
Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades'
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
Eli Lilly’s Path to the Next Trillion Market Capitalization
Via MarketBeat
3 Unstoppable Dividend Stocks to Buy Right Now
Via The Motley Fool
US Stocks May Take a Breather After S&P 500's Impressive 8-Session Winning Streak: Strategist Says Market Will Hit Fresh Highs In Next 4 Weeks, But Warns Investors Of Potential Risks
Via Benzinga
Topics Stocks
Exposures US Equities
ProInvestor Insights - August 2024
Via Talk Markets
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Via Investor's Business Daily
MarketBeat Week in Review – 8/5 - 8/9
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.